| 产品描述: | GW405833 (L768242) hydrochloride is a potent, selective cannabinoid receptor 2 (CB2) agonist. GW405833 has EC50 and Ki values of 0.65 nM and 3.92 nM for CB2, and EC50 and Ki values of 16.1 μM and 4772 nM for CB1. GW405833 hydrochloride also exhibits non-competitive CB1 antagonist, exerting its analgesic effect through a CB1 receptor (rather than CB2) dependent mechanism. GW405833 hydrochloride can significantly inhibit the production of cAMP stimulated by Forskolin . GW405833 hydrochloride inhibits glycolysis by down-regulating HIF-1α, thereby alleviating acute liver failure (ALF). |
| 靶点: |
CB2 :50.7 nM (IC50); CB1 :16.1 μM (IC50); IL-1β;HIF-1α |
| 体外研究: |
GW405833 (3-30 mg/kg,腹腔注射,单次剂量) hydrochloride 通过 CB1 受体而非 CB2 受体剂量依赖性地逆转小鼠神经性疼痛和炎症性疼痛模型中的机械性异常疼痛,并且不会产生典型的大麻素样作用[1]。 GW405833 (3 mg/kg,静脉注射,单次剂量) hydrochloride 通过减少细胞因子产生和氧化应激来抑制大鼠的炎症和脚部水肿[3]。 GW405833 (10 mg/kg,腹腔注射,单次剂量) hydrochloride 可通过下调 HIF-1α 来抑制糖酵解防止急性肝衰竭 (ALF) 大鼠模型中的细胞死亡[5]。 |
| 体内研究: |
GW405833 hydrochloride在人、小鼠和大鼠脾膜中表现为低效激动剂,并在 hCB2-CHO 细胞中表现出反向激动剂作用。 GW405833 (10 μM,25 h) hydrochloride 通过下调 HIF-1α 来抑制糖酵解,从而抑制肝巨噬细胞增殖。 |
| 保存条件: |
-80°C 12个月; -20°C 6个月, 干燥 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.067 ml |
10.334 ml |
20.669 ml |
| 5 mM |
0.413 ml |
2.067 ml |
4.134 ml |
| 10 mM |
0.207 ml |
1.033 ml |
2.067 ml |
| 50 mM |
0.041 ml |
0.207 ml |
0.413 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |